-
Patient Perspectives on Unmet Needs in mCRPC: Emphasizing Improved Quality of Life and Delay in Chemotherapy
Sep 9, 2025, 16:22 PM -
Diagnostic Odyssey of Patients With the Rare Immunodeficiency-Activated PI3 Kinase Delta Syndrome (APDS): Case Study With Expert Interviews and Patient Surveys
Sep 9, 2025, 16:22 PM -
Site of Care Cost-Effectiveness of Axicabtagene Ciloleucel in Relapsed/Refractory Second-Line or Later Large B-cell Lymphoma in the United States: Analyses for Inpatient and Outpatient Infusion Settings
Sep 9, 2025, 16:22 PM -
Get Real: A How-to Framework on Designing and Implementing a Regulatory and HTA-Grade External Comparator Study
Sep 9, 2025, 16:22 PM -
AI in Pragmatic Literature Reviews: A Scoping Review of Current Guidance and Development of a Framework for Integration
Sep 9, 2025, 16:22 PM -
Generating Data for Diversity Planning in Breast Cancer: A Multi-Database Validation Study Using US Claims and HER, Population Census, and Cancer Registry Data in the United States
Sep 9, 2025, 16:22 PM -
Innovation on Hold: A 2020-2025 Analysis of the Conditional Drug Reimbursement Framework
Sep 9, 2025, 16:22 PM -
A Comprehensive Assessment of Clinical Studies on Artificial Intelligence-Enabled Interventions: Uncovering Trends and Potential Implications
Sep 9, 2025, 16:22 PM -
Cost of Treatment of Metastatic Non-Small Lung Cancer in Sweden, 2011-2023
Sep 9, 2025, 16:22 PM -
Comprehensive Uncertainty Assessment in Economic Evaluations of AI-Based Health Technologies: Pitfalls and Recommendations
Sep 9, 2025, 16:22 PM -
The PHEBUS Study: A Retrospective Analysis of the Burden of Pneumococcal Infections in the Pediatric Population Using the French Hospital Discharge Database (PMSI)
Sep 9, 2025, 16:22 PM -
Balancing Fit and Accuracy: Evaluating Survival Model Projections With Immature Data in Health Technology Assessments
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of Ocrelizumab for Treating Relapsing Multiple Sclerosis in Austria
Sep 9, 2025, 16:22 PM -
The Economic Case for Gender Equity: How Closing the Women’s Health Gap Benefits Healthcare Systems and Economies
Sep 9, 2025, 16:22 PM -
From Evidence to Enforcement? Implications of the 2025 SVR Report for Pharmaceutical Pricing and Orphan Drug Policy in Germany
Sep 9, 2025, 16:22 PM -
Assessment of Health State Utilities Associated With Treatment for Chronic Hepatitis B Virus (HBV) Infection
Sep 9, 2025, 16:22 PM -
HTA Readiness for Tumor-Agnostic Therapies: Lessons From Analogues Across Major Markets
Sep 9, 2025, 16:22 PM -
Clinical Benefit vs. Reimbursement Decisions: Examining Misalignments Between ESMO-MCBS and HTA Outcomes in Oncology
Sep 9, 2025, 16:22 PM -
Physician Perspectives on Unmet Need and Treatment Options Among Patients With Relapsed Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Canada: Findings From Qualitative Interviews
Sep 9, 2025, 16:22 PM -
Landscape Analysis of Initiatives to Improve Access to Orphan Drugs Led by Industry Patient and Academic Stakeholders
Sep 9, 2025, 16:22 PM
